Source: yahoo_news
Source ID: yahoo:2202c037c8d6e608c62fa27eb0ada757:PALI
URL: https://finance.yahoo.com/healthcare/articles/palisade-bio-expands-global-phase-124500013.html?.tsrc=rss
Symbol: (PALI)
Published: 2026-09-23 08:45:00 EDT
Time precision: minute
Title: Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance

Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027 Denver, CO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic dis